



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 28, 2020

Via E-mail

Mr. John M. Sprague  
Chief Financial Officer  
T2 Biosystems, Inc.  
101 Hartwell Avenue  
Lexington, MA 02421

**Re: T2 Biosystems, Inc.**  
**Form 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.1 Amendment No. 5 To Term Loan Agreement**  
**Filed November 18, 2019**  
**File No. 001-36571**

**Form 10-Q/A for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.2 Contract**  
**Filed November 20, 2019**  
**File No. 001-36571**

Dear Mr. Sprague:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance